Repligen | RGEN - Pre Tax Profit


Repligen reported $19.11M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Agilent USD 364M 78M Dec/2025
Align Technology USD 148.89M 27.71M Mar/2026
Bio Techne USD 50.78M 34.21M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Bruker USD 68.2M 140.8M Dec/2025
Charles River Laboratories USD -294.1M 464.13M Dec/2025
Danaher USD 1.24B 138M Mar/2026
Dentsply International USD -42M 105M Mar/2026
General Electric Aerospace USD 2.2B 654M Mar/2026
Henry Schein USD 150M 17M Mar/2026
Illumina USD 157M 220M Mar/2026
IQVIA Holdings USD 6.22B 5.68B Mar/2026
Mettler Toledo International USD 329.07M 59.84M Dec/2025
Myriad Genetics USD 4.6M 3.4M Dec/2025
OraSure Technologies USD -18.43M 5.14M Dec/2025
Pacific Biosciences Of California USD -40.17M 2.55M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Repligen USD 19.11M 2M Dec/2025
Revvity USD 91.56M 35.88M Dec/2025
Standard Biotools USD -22.03M 10.87M Dec/2025
Thermo Fisher Scientific USD 2.12B 295M Dec/2025
Waters USD 264.18M 94.06M Dec/2025
West Pharmaceutical Services USD 161.5M 8.6M Dec/2025